BACKGROUND: Diabetic foot infections (DFIs) contribute to the global disability burden. Beta-lactams are the most commonly used antibiotics for treating DFIs. However, the use of antibiotics may lead to disruption of the healthy balance of the gut microbiota, causing dysbiosis. METHODS: Patients with infected diabetic foot ulcers (iDFUs) were treated with two kinds of beta-lactams (amoxicillin/clavulanic acid or ceftazidime) according to microbial sensitivity of causative agents via bolus or continuous administration modes. Changes in the gut microbiome of patients were analyzed. Diabetic patients without iDFUs were used as a control group. 16 S ribosomal RNA gene amplicon sequencing was performed on stool samples collected from participants. RESULTS: Alpha diversity and beta diversity of gut microbiota of treated patients did not show significant differences between bolus and continuous modes. However, significant differences were observed between gut microbiota diversity of treated patients and control group. PCoA plots showed individualized responses of the patient's gut microbiota to antibiotics at different times using both administration forms associated with the pre-treatment state of microbiota composition. Enterococcus, Sellimonas, and Lachnoclostridium were the common bacterial markers differentially abundant in the gut microbiota of antibiotic-treated patients with iDFUs while Roseburia, Dorea, and Monoglobus were mainly abundant in the gut microbiota of patients without iDFUs. Predicted pathways like "Transporters", "ABC transporters" and "Phosphotranspherase system (PTS)" were upregulated in the gut microbiome of patients treated with bolus regime which may lead to increased intestinal barrier permeability. CONCLUSION: The present study reported alterations in gut microbiota composition and functionality and provided the bacterial markers as well as potential metabolic signatures associated with each administration mode in patients with iDFUs, which may be used as a reference set for future studies of the effect of antibiotics administration on the gut microbiome of patients with iDFUs. This study shed light on the importance of understanding the effect of antibiotic administration form on gut microbiome in patients with iDFUs. TRIAL REGISTRATION: The DFIATIM Clinical Trial (Full title: "Rationalisation of ATB therapy in diabetic foot infection and its impact on the intestinal microbiota") is submitted to the European Union Clinical Trials Database under the EudraCT Number: 2019-001997-27. The date of registration is July 17th, 2020.

• Klíčová slova
• Antibiotics, Beta-lactam, Bolus, Continuous, Diabetes, Diabetic foot infection, Diabetic foot ulcers, Gut microbiota,
• MeSH
• antibakteriální látky * aplikace a dávkování   terapeutické užití   MeSH
• Bacteria klasifikace   genetika   účinky léků   izolace a purifikace   MeSH
• ceftazidim aplikace a dávkování   terapeutické užití   MeSH
• diabetická noha * farmakoterapie   mikrobiologie   MeSH
• dysbióza mikrobiologie   MeSH
• feces mikrobiologie   MeSH
• kombinace amoxicilinu a kyseliny klavulanové aplikace a dávkování   MeSH
• lidé středního věku MeSH
• lidé MeSH
• RNA ribozomální 16S genetika   MeSH
• senioři MeSH
• střevní mikroflóra * účinky léků   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• antibakteriální látky * MeSH
• ceftazidim MeSH
• kombinace amoxicilinu a kyseliny klavulanové MeSH
• RNA ribozomální 16S MeSH